Biblio

33557 resultats trouvés
R
Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, de Billy B, Linglart A, Wicart P.  2016.  Results of Orthopaedic Surgery in Children with X-Linked Hypophosphatemic Rickets (XLHR). HORMONE RESEARCH IN PAEDIATRICS. 86:74.
Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, de Billy B, Linglart A, Wicart P.  2016.  Results of Orthopaedic Surgery in Children with X-Linked Hypophosphatemic Rickets (XLHR). HORMONE RESEARCH IN PAEDIATRICS. 86:74.
Curtit E, Vannetzel J-M, Darmon J-C, Roche S, Bourgeois H, Dewas S, Catala S, Mereb E, Fanget CFurtos, Genet D et al..  2019.  Results of PONDx, a prospective multicenter study of the Oncotype DX (R) breast cancer assay: Real-life utilization and decision impact in French clinical practice. BREAST. 44:39-45.
Duffaud F, Blay J-Y, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A et al..  2018.  Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.. JOURNAL OF CLINICAL ONCOLOGY. 36
Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, Costa V, Yakouben K, Paillard C, Uyttebroeck A et al..  2019.  Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL). BRITISH JOURNAL OF HAEMATOLOGY. 186:741-753.
Jolly D, Ambrosi P, Chaffanjon P, Dreyfuss D, Le Jeunne C, Lorette G, Obert L, Palombi O, Romanet J-P.  2014.  Results of the 2013 national ranking in France. PRESSE MEDICALE. 43:865–867.
Jolly D, Ambrosi P, Chaffanjon P, Dreyfuss D, Le Jeunne C, Lorette G, Obert L, Palombi O, Romanet J-P.  2015.  Results of the 2014 National Ranking in France. PRESSE MEDICALE. 44:533-535.
Jolly D, Ambrosi P, Chaffanjon P, Dreyfuss D, Le Jeunne C, Lorette G, Obert L, Palombi O, Romanet J-P.  2016.  Results of the 2015 national ranking in France. PRESSE MEDICALE. 45:133-142.
de Latour RPeffault, Marsh J, Iacobelli S, Terwel S, Hill A, Halkes CJM, Recher C, Barraco F, Forcade E, Llamas JCarlos Val et al..  2020.  Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients. BONE MARROW TRANSPLANTATION. 55:12-13.
Bonnetain F., de Bausset M., Hammel P., Lledo G., Obled S., Ychou M..  2016.  Results of the French National REPERE Survey regarding Pancreatic Cancer Patients' Care. EUROPEAN JOURNAL OF CANCER. 57:S7.
Bonnetain F., de Bausset M., Hammel P., Lledo G., Obled S., Ychou M..  2016.  Results of the French National REPERE Survey regarding Pancreatic Cancer Patients' Care. EUROPEAN JOURNAL OF CANCER. 57:S7.
Zulfiqar A-A, Vaudelle O, Hajjam M, Geny B, Talha S, Letourneau D, Hajjam J, Erve S, Hassani AHajjam El, Andres E.  2020.  Results of the ``GER-e-TEC'' Experiment Involving the Use of an Automated Platform to Detect the Exacerbation of Geriatric Syndromes. JOURNAL OF CLINICAL MEDICINE. 9:3836.
Pautier P., Penel N., Ray-Coquard I., Italiano A., Bompas E., Delcambre C., Bay J-O., Bertucci F., Delaye J., Chevreau C. et al..  2017.  Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study. ANNALS OF ONCOLOGY. 28
Piccart M., M. Borrego R, Duhoux F., Arkenau H-T., B. de Speville D, Wildiers H., Campone M., Tosi D., Garcia-Corbacho J., Jimenez B. et al..  2020.  Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC). ANNALS OF ONCOLOGY. 31:S386.
Blanc J.-F, Khemissa F., Bronowicki J.-P, Monterymard C., Perarnau J.-M, Bourgeois V., Obled S., Abdelghani M.B, Mabile-Archambeaud I., Faroux R. et al..  2018.  Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients. JOURNAL OF HEPATOLOGY. 68:S195.
Westeel V., Barlesi F., Foucher P., Lafitte J-J., Domas J., Girard P., Tredaniel J., Wislez M., Dumont P., Quoix E. et al..  2017.  Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY. 28
Azria D., Crehange G., Castan F., Schwartz E., Belkacemi Y., Lagrange J., Nguyen T., Chapet O., Mornex F., Noel G. et al..  2019.  Results of the prospective trial evaluating radiation-induced lymphocyte apoptosis and prostate RT. RADIOTHERAPY AND ONCOLOGY. 133:S256.
Duffaud F., Blay J-Y., Mir O., Chevreau C.M, P. Rouquette B, Kalbacher E., Penel N., Perrin C., Laurence V., Bompas E. et al..  2020.  Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. ANNALS OF ONCOLOGY. 31:S1199.
Duffaud F., Chabaud S., Chevreau C.M, Italiano A., Perrin C., Isambert N., Piperno-Neumann S., Saada-Bouzid E., Bertucci F., Cupissol D. et al..  2021.  Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer. ANNALS OF ONCOLOGY. 32:S1335.
Zulfiqar A-A, Massimbo DNoaga Dami, Hajjam M, Geny B, Talha S, Hajjam J, Erve S, Hajjam A, Andres E.  2021.  Results of the Second Phase of the GER-e-TEC Experiment concerning the Telemonitoring of Elderly Patients Affected by COVID-19 Disease to Detect the Exacerbation of Geriatric Syndromes. JOURNAL OF PERSONALIZED MEDICINE. 11:1117.
Dubouis A, Vernier-Mosca M, Rinckenbach S, Mont LSalomon Du.  2021.  Results of the Surgical Management of Acute Limb Ischemia in the Nonagenarians. ANNALS OF VASCULAR SURGERY. 70:378-385.
Ray-Coquard ILaure, Alexandre J, Goldwasser F, Spano J-P, Berton-Rigaud D, Savoye A-M, Fabbro M, Bazan F, Kalbacher E, Raban N et al..  2019.  Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)-A real-life ambispective study.. JOURNAL OF CLINICAL ONCOLOGY. 37
Courtaut F, Aires V, Acar N, Bretillon L, Guerrera IChiara, Chhuon C, de Barros J-PPais, Olmiere C, Delmas D.  2021.  RESVEGA, a Nutraceutical Omega-3/Resveratrol Supplementation, Reduces Angiogenesis in a Preclinical Mouse Model of Choroidal Neovascularization. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 22:11023.
Azzaz JAl, Tarraf AAl, Heumann A, Barreira DDa Silva, Laurent J, Assifaoui A, Rieu A, Guzzo J, Lapaquette P.  2020.  Resveratrol Favors Adhesion and Biofilm Formation ofLacticaseibacillus paracasei subsp. paracaseiStrain ATCC334. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 21:5423.
Pasquereau S, Nehme Z, Ahmad SHaidar, Daouad F, Van Assche J, Wallet C, Schwartz C, Rohr O, Morot-Bizot S, Herbein G.  2021.  Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. VIRUSES-BASEL. 13:354.

Pages